Athena Cherry

Publication Details

  • B-Cell Transcription Factor Expression and Immunoglobulin Gene Rearrangement Frequency in Acute Myeloid Leukemia With t(8;21)(q22;q22) AMERICAN JOURNAL OF CLINICAL PATHOLOGY Johnson, R. C., Ma, L., Cherry, A. M., Arber, D. A., George, T. I. 2013; 140 (3): 355-362

    Abstract:

    Objectives: To assess a large series of patients with acute myeloid leukemia (AML) with t(8;21) for both IGH@ and IGK@ B-cell gene rearrangements and for expression of PAX5, OCT2, and Bob.1 by immunohistochemistry and expression of CD19, CD79a, CD20, and CD22 by flow cytometry immunophenotyping. Methods: A total of 48 cases of AML with t(8;21)(q22;q22) were evaluated by immunohistochemistry and/or heavy chain and light chain immunoglobulin rearrangement studies where paraffin-embedded and/or fresh frozen material was available for study; previously performed flow cytometry studies were also reviewed in available cases. Results: Our study yielded 1 of 19 cases of AML with t(8;21) with an IGH@ gene rearrangement; blasts were associated with weak PAX5 expression. In addition, expression of antigens CD79a by flow cytometry and OCT2 by immunohistochemistry were highly associated with PAX5 expression, and CD19 was expressed in most cases assessed. Conclusions: Although B-cell antigen and B-cell transcription factor expression is seen in the majority of AMLs with t(8;21)(q22;q22) and correlates with PAX5 expression, immunoglobulin gene rearrangements are an uncommon event in this group of leukemias.

    View details for DOI 10.1309/AJCPFBCFXP94AKWJ

    View details for Web of Science ID 000323359800011

    View details for PubMedID 23955454

Stanford Medicine Resources:

Footer Links: